About N-of-One
N-of-One is a company based in Lexington (United States) founded in 2008 was acquired by Qiagen in January 2019. N-of-One has raised $17.75 million across 6 funding rounds from investors including Philips, Qiagen and Excel Venture Management. N-of-One operates in a competitive market with competitors including Denali Therapeutics, Castle Biosciences, Juno Therapeutics, Atrys and Unity Biotechnology, among others.
- Headquarter Lexington, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of N-of-One
N-of-One has successfully raised a total of $17.75M across 6 strategic funding rounds. The most recent funding activity was a Series B round of $7 million completed in January 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in N-of-One
N-of-One has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include Philips, Qiagen and Excel Venture Management.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early to late stage VC firm investing in the US
|
Locked | Locked | Locked | |
|
Venture capital firm
|
Locked | Locked | Locked | |
|
Products and reagents for molecular diagnostic assays are supplied.
|
Locked | Locked | Locked |
Investor details for N-of-One
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by N-of-One
Investment portfolio details for N-of-One
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - N-of-One
Detailed financials for N-of-One
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
N-Of-One Comparisons
Peer comparison for N-of-One
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of N-of-One
N-of-One operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Denali Therapeutics, Castle Biosciences, Juno Therapeutics, Atrys and Unity Biotechnology, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's.
|
|
| Locked | Locked | Locked |
Precision diagnostic and prognostic tests are developed by Castle Biosciences.
|
|
| Locked | Locked | Locked |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed.
|
|
| Locked | Locked | Locked |
Provider of diagnostic and therapeutic services catering to cancer
|
|
| Locked | Locked | Locked |
Therapeutics for aging diseases are developed by targeting senescent cells.
|
|
| Locked | Locked | Locked |
Diagnostic services are provided through laboratories and radiology units.
|
Detailed competitors of N-of-One
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on N-Of-One
Complete news archive for N-of-One
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about N-of-One
N-of-One was founded in 2008 and raised its 1st funding round 3 years after it was founded.
N-of-One is headquartered in Lexington, United States. It is registered at Lexington, Kentucky, United States.
N-of-One is a funded company, having raised a total of $17.75M across 6 funding rounds to date.
N-of-One was founded in 2008 and is based in Lexington, United States. Operations focus on the healthcare sector, where tumor molecular profiles are interpreted to guide physicians in diagnostics and treatments. Services include Precision Insights for NGS panel reports and TrialMatch for matching patients to clinical trials based on molecular data. Decision support is provided to clinicians without functioning as a diagnostic lab or bioinformatics provider.
N-of-One's top competitors include Juno Therapeutics, Ambrx and Denali Therapeutics.
N-of-One has 4 investors. Key investors include Philips, Qiagen, Excel Venture Management, and Allumia Ventures.